We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+30.64%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.06B
AUM Growth
+$264M
Cap. Flow
+$103M
Cap. Flow %
9.71%
Top 10 Hldgs %
50.25%
Holding
118
New
40
Increased
18
Reduced
23
Closed
31

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$50.2M
2
NICE icon
Nice
NICE
+$22.7M
3
AMGN icon
Amgen
AMGN
+$18.3M
4
AZN icon
AstraZeneca
AZN
+$16.5M
5
LLY icon
Eli Lilly
LLY
+$13.8M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$22.4M
2
PFE icon
Pfizer
PFE
+$19.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$18.3M
4
NVO
Novo Nordisk
NVO
+$11.2M
5
XLP icon
State Street Consumer Staples Select Sector SPDR ETF
XLP
+$7.91M

Sector Composition

Rank Sector Weight
1 Healthcare 64.11%
2 Technology 8.21%
3 Consumer Discretionary 1.63%
4 Industrials 1.41%
5 Communication Services 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOK
26
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$9.66M 0.91%
+100,000
New +$8.34M
WIX icon
27
WIX.com
WIX
$2.3B
$9.63M 0.91%
+37,588
New +$6.67M
IOVA icon
28
Iovance Biotherapeutics
IOVA
$1.82B
$9.55M 0.9%
+348,000
New +$11.4M
TRIL
29
DELISTED
Trillium Therapeutics Inc.
TRIL
$9.53M 0.9%
1,178,346
-82,348
-7% -$509K
KRNT icon
30
Kornit Digital
KRNT
$705M
$9.42M 0.89%
+176,507
New +$6.73M
PASG icon
31
Passage Bio
PASG
$14.4M
$9.41M 0.89%
17,222
-6,687
-28% -$3.01M
FISV
32
Fiserv Inc
FISV
$28.8B
$9.3M 0.87%
+95,246
New +$9.59M
KURA icon
33
Kura Oncology
KURA
$800M
$8.71M 0.82%
+534,494
New +$7.71M
MRTX
34
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.22M 0.77%
+72,000
New +$6.98M
SIOX
35
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$8.06M 0.76%
2,857,998
-73,020
-2% -$234K
FATE icon
36
Fate Therapeutics
FATE
$286M
$7.72M 0.73%
+225,000
New +$6.71M
RPTX
37
DELISTED
Repare Therapeutics
RPTX
$7.6M 0.71%
+245,000
New +$7.86M
KPTI icon
38
Karyopharm Therapeutics
KPTI
$43.5M
$7.44M 0.7%
26,189
-10,478
-29% -$3.1M
TEVA icon
39
Teva Pharmaceuticals
TEVA
$40.8B
$7.19M 0.68%
582,878
+226,165
+63% +$2.56M
RCKT icon
40
Rocket Pharmaceuticals
RCKT
$340M
$7.12M 0.67%
340,016
+5,000
+1% +$90.1K
CNCE
41
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$6.97M 0.66%
700,710
-312,329
-31% -$3M
PANW icon
42
Palo Alto Networks
PANW
$270B
$6.89M 0.65%
180,000
+81,288
+82% +$2.86M
SEDG icon
43
SolarEdge
SEDG
$2.51B
$6.39M 0.6%
+46,017
New +$5.63M
APRE icon
44
Aprea Therapeutics
APRE
$7.68M
$6.14M 0.58%
+7,914
New +$5.19M
KRYS icon
45
Krystal Biotech
KRYS
$10.1B
$5.99M 0.56%
+144,573
New +$6.96M
ITCI
46
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.87M 0.55%
+228,700
New +$4.63M
ADMA icon
47
ADMA Biologics
ADMA
$1.96B
$5.82M 0.55%
1,984,949
+146,849
+8% +$422K
DOV icon
48
Dover
DOV
$27.6B
$5.56M 0.52%
+57,576
New +$5.32M
DPZ icon
49
Domino's
DPZ
$11.5B
$5.37M 0.5%
+14,521
New +$5.35M
XFOR icon
50
X4 Pharmaceuticals
XFOR
$375M
$5.27M 0.5%
18,860
-10,247
-35% -$2.81M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sphera Funds Management held 118 positions worth $1.06B, up 33% from $800M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management deployed $103M of net new capital in Q2 2020, opening 40 new positions and adding to 18 existing holdings. Its largest new stake was Nice: 129,406 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 66% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $18.3M trimmed.

  • Sphera Funds Management's largest Q2 2020 buy was Nice: 129,406 shares worth $24.5M.
  • Sphera Funds Management added most to AbbVie in Q2 2020, an estimated $50.2M increase.
  • Sphera Funds Management's biggest Q2 2020 reduction was Sarepta Therapeutics, cutting an estimated $18.3M.
  • Sphera Funds Management fully exited Alexion Pharmaceuticals in Q2 2020, selling an estimated $22.4M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.06B portfolio in Q2 2020.
  • Sphera Funds Management opened 40 new positions and closed 31 in Q2 2020.
  • Sphera Funds Management's portfolio value rose 33% quarter-over-quarter to $1.06B.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.